Skip to main content
. 2021 Oct 20;3(4):100219. doi: 10.1016/j.ocarto.2021.100219

Table 3.

Identification of 12 significantly modulated phosphatidylcholines between early- and late-stage OA SF by MRM/MS lipidomic analysis.

N Lipid species m/z MS mode eOA (n ​= ​7) lOA (n ​= ​8) FC p-value
1 D-α-PC dipalmitoyl 734.60 POS 4420.00 ​± ​1451.00 2033.00 ​± ​743.80 2.44 0.001
2 PC 28:1 676.50 POS 829.40 ​± ​389.50 322.10 ​± ​126.70 2.58 0.003
3 PC 30:0 706.50 POS 1034.00 ​± ​385.50 454.40 ​± ​147.40 2.55 0.001
4 PC 30:1 704.50 POS 6789.00 ​± ​2060.00 4169.00 ​± ​1777.00 1.63 0.001
5 PC 30:2 702.50 POS 1413.00 ​± ​539.10 684.10 ​± ​317.10 2.07 0.004
6 PC 32:1 732.60 POS 4342.00 ​± ​1465.00 2057.00 ​± ​741.40 2.37 0.002
7 PC 32:2 730.50 POS 2490.00 ​± ​683.00 1098.00 ​± ​333.00 2.54 0.000
8 PC 34:1 760.60 POS 667.30 ​± ​285.40 311.80 ​± ​80.76 2.39 0.003
9 PC 34:2 758.60 POS 16386.00 ​± ​3784.00 9784.00 ​± ​3116.00 1.67 0.001
10 PC 36:0 790.60 POS 18282.00 ​± ​5341.00 12515.00 ​± ​3860.00 1.46 0.031
11 PC 36:2 786.60 POS 2682.00 ​± ​1084.00 1354.00 ​± ​621.90 1.98 0.011
12 PCaa 24:0 622.44 POS 16992.00 ​± ​4246.00 11444.00 ​± ​3658.00 1.48 0.017

eOA: early-stage osteoarthritis; lOA: late-stage osteoarthritis; POS: positive ion mode; FC: fold change; PC: phosphatidylcholine.

∗significant difference from control SF.

#significant difference between eOA and lOA.